← Back to Gland Pharma Ltd. overview
Gland Pharma Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹5,584 cr | ₹699 cr | ₹42.4 | ₹11,225 cr | ₹9,151 cr | 7.63% | 11.62% | 0.03x | 12.51% |
| FY2024 | ₹5,642 cr | ₹772 cr | ₹46.89 | ₹10,661 cr | ₹8,724 cr | 8.85% | 12.69% | 0.04x | 13.69% |
| FY2023 | ₹3,592 cr | ₹781 cr | ₹47.43 | ₹8,778 cr | ₹7,959 cr | 9.81% | 13.32% | 0x | 21.74% |
| FY2022 | ₹4,384 cr | ₹1,212 cr | ₹73.64 | ₹7,834 cr | ₹7,158 cr | 16.93% | 22.65% | 0x | 27.64% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.